Daclatasvir and Asunaprevir in Non-Japanese Asian Patients With Chronic HCV Genotype 1b Infection who are Ineligible for or Intolerant to Interferon-alfa Therapies With or Without Ribavirin: Phase 3 SVR12 Interim Results
第一作者单位:[1]Peking Univ Peoples Hosp, Beijing, Peoples R China[2]Peking Univ, Inst Hepatol, Beijing, Peoples R China
推荐引用方式(GB/T 7714):
Wei Lai,Zhang Mingxiang,Xu Min,et al.Daclatasvir and Asunaprevir in Non-Japanese Asian Patients With Chronic HCV Genotype 1b Infection who are Ineligible for or Intolerant to Interferon-alfa Therapies With or Without Ribavirin: Phase 3 SVR12 Interim Results[J].HEPATOLOGY.2015,62(6):1391A-1391A.
APA:
Wei, Lai,Zhang, Mingxiang,Xu, Min,Chuang, Wan-Long,Lu, Wei...&Mo, Ling.(2015).Daclatasvir and Asunaprevir in Non-Japanese Asian Patients With Chronic HCV Genotype 1b Infection who are Ineligible for or Intolerant to Interferon-alfa Therapies With or Without Ribavirin: Phase 3 SVR12 Interim Results.HEPATOLOGY,62,(6)
MLA:
Wei, Lai,et al."Daclatasvir and Asunaprevir in Non-Japanese Asian Patients With Chronic HCV Genotype 1b Infection who are Ineligible for or Intolerant to Interferon-alfa Therapies With or Without Ribavirin: Phase 3 SVR12 Interim Results".HEPATOLOGY 62..6(2015):1391A-1391A